Virtuell gåterapi for nevropatiske smerter etter ufullstendig ryggmargsskade
The purpose of this study is to determine if playing a virtual reality walking game can help improve neuropathic pain in adults with incomplete spinal cord injury.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
Many people with SCI experience neuropathic pain. Neuropathic pain is often described as sharp, burning, or electric. 'Traditional' treatments often do not do a good job of reducing neuropathic pain. Therefore, it is important to see if 'non-traditional' treatments might work. Scientists think that neuropathic pain occurs in SCI because the sensations coming from the eyes and up the spinal cord to the brain do not match what the brain thinks it told the body to do. This 'mismatch' may result in changes in the brain that make neuropathic pain possible. Virtual reality walking may potentially reduce this 'mismatch' by creating the 'illusion' that the person is walking. The brain then thinks it is telling the body to walk AND the information coming from the eyes matches its instructions. This 'matching' may reverse the brain changes that make neuropathic pain possible. The current study is specifically focused on individuals whose SCI has been classified as incomplete (ASIA B, C, or D).
Studietype
Registrering (Antatt)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
- Navn: Ami Lisenbee
- Telefonnummer: 804-569-5965
- E-post: sci@vrwalk.org
Studiesteder
-
-
Texas
-
College Station, Texas, Forente stater, 77843
- Rekruttering
- Texas A&M University
-
Hovedetterforsker:
- Zina Trost, PhD
-
Ta kontakt med:
- Ami Lisenbee
- Telefonnummer: 804-569-5965
- E-post: sci@vrwalk.org
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
The study will recruit individuals with incomplete injury (American Spinal Injury Association [ASIA] classification B, C, or D) with lumbar, paraplegic, or low tetraplegic (C5-C7) injury. Additional criteria will include:
- Must have persistent NP symptoms that are of daily severity of at least 4/10 for 3 or more months
- Must endorse more than 2 items on a 7-item Spinal Cord Injury Pain Instrument, SCIPI
- Must be 18 years of age or older
- Must be more than one and a half years post-injury to begin study (can be screened at an earlier time for eligibility)
- Must have mobile connectivity with usable service
- Must be stable on pain medication for 1 or more months
- Must be cleared on the VRWalk physical activity clearance scale
- Must not have motion sickness that interferes with daily life
- Must use a wheelchair at least 75% of the time
Exclusion Criteria:
- Individuals with Injury levels between C1 and C4
- Individuals under the age of 18
- Individuals who were injured within the past year
- Individuals who cannot comprehend spoken English
- Individuals who are in prison
- Individuals who are blind
- Individuals who experience severe motion sickness
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Trippel
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Aktiv komparator: Virtual reality (VR) game 1
Participants will be asked to play a virtual reality game twice a day for 10 days. |
Individuals playing VR game 1 will wear a head-mounted display to allow them to visualize virtual legs in the virtual environment. When wearing the display, individuals will see the legs and arms of their virtual avatar from a first-person perspective. Individuals will engage in virtual reality sessions in their home twice daily over the course of 10 days in a two-week period. Each daily session will take approximately 30 minutes, with 5-10 minutes dedicated to the virtual walking experience. Additionally, each daily session will be scheduled a minimum of 4 hours apart |
|
Aktiv komparator: Virtual reality (VR) game 2
Participants will be asked to play a virtual reality game twice a day for 10 days. |
Individuals playing VR game 2 will wear a head-mounted display to allow them to visualize virtual legs in the virtual environment. When wearing the display, individuals will see the legs and arms of their virtual avatar from a first-person perspective. Individuals will engage in virtual reality sessions in their home twice daily over the course of 10 days in a two-week period. Each daily session will take approximately 30 minutes, with 5-10 minutes dedicated to the virtual walking experience. Additionally, each daily session will be scheduled a minimum of 4 hours apart. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in Pain Intensity
Tidsramme: Baseline - final follow up (up to 18 months)
|
The Numeric Rating Scale (NRS) measures pain intensity via a 0-10 numeric rating scale 0-10 where 0 is no pain, and 10 is the worst pain imaginable. |
Baseline - final follow up (up to 18 months)
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in Pain Quality
Tidsramme: Baseline - final follow up (up to 18 months)
|
The Neuropathic Pain Scale (NPS) assesses the distinct pain qualities, including sharpness, heat/cold, dullness, intensity, overall unpleasantness, and surface vs. deep pain. The NPS consists of 10 items. 0 equals 'No sensation' and 10 equals 'Worst sensation imaginable.' All the items are rated 0-10 scale, with a higher score indicative of more neuropathic pain for each type of respective pain. |
Baseline - final follow up (up to 18 months)
|
|
Change in Pain Interference
Tidsramme: Baseline - final follow up (up to 18 months)
|
The International Spinal Cord Injury Pain Basic Data Set version 2.0 interference assesses the degree to which pain interferes with day-to-day activities, mood, and sleep. Items are scored on a 0-10 numeric rating scale, and scores are summed to yield an interference score ranging from 0 to 30. Higher scores indicate greater interference from pain. |
Baseline - final follow up (up to 18 months)
|
|
Post treatment change
Tidsramme: at follow up (up to 18 months)
|
The Patient Global Impression of Change is a one item 7 point Likert item assessing improvement of the participants' overall status. A score of 1 is 'Very Much Improved', and a score of 7 is 'Very Much Worse.' Higher scores indicate less perceived improvement. Range of scores: 1-7 |
at follow up (up to 18 months)
|
|
Change in mood
Tidsramme: Baseline - final follow up (up to 18 months)
|
Mood will be assessed using the Patient Health Questionnaire-9. Participants will be asked to rate how often they have been bothered by specific problems on a 4-point Likert scale, where 0 is 'Not at all,' and 3 is 'Nearly every day.' The items are summed to yield a score ranging from 0-27. Higher scores indicate worse mood. |
Baseline - final follow up (up to 18 months)
|
|
Change in quality of life
Tidsramme: Baseline - final follow up (up to 18 months)
|
Quality of life is assessed by the Satisfaction with Life Scale. This is a 5 item survey. Response options are a 7-point Likert scale where 1 is 'Strongly disagree,' and 7 is 'Strongly agree'. Items may be assessed individually or by summing items. Range of scores: 5-35. Higher scores indicate more satisfaction in life |
Baseline - final follow up (up to 18 months)
|
|
Neurological changes
Tidsramme: Baseline - 6 months
|
For eligible and interested participants, functional Magnetic Resonance Imaging (fMRI) will be used to observe neurological changes. Pre and post-study images will be compared by experienced researchers. |
Baseline - 6 months
|
Samarbeidspartnere og etterforskere
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- SC220178
- SC220178 (Annet stipend/finansieringsnummer: Congressionally Directed Medical Research Programs)
- HT9425-23-1-1019 (Annet stipend/finansieringsnummer: Department of Depense)
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .